摘要 |
<p>The present application discloses a product comprising (i) as a first component vemurafenib, and (ii) as a second component an MDM2 inhibitor selected from compounds (II) or (III), or a pharmaceutically acceptable salt thereof, for the sequential or concomitant use in the treatment of proliferative diseases, such as cancer, involving b-Raf V600 mutant positive tumor.</p> |
申请人 |
F. HOFFMANN-LA ROCHE AG;HIGGINS, BRIAN;KOLINSKY, KENNETH;NICHOLS, GWEN;PACKMAN, KATHRYN E.;SU, FEI |
发明人 |
HIGGINS, BRIAN;KOLINSKY, KENNETH;NICHOLS, GWEN;PACKMAN, KATHRYN E.;SU, FEI |